INS and Hyperglycemia: This is in contrast to several non-specific immunomodulatory agents, such as anti-CD3 mAb, that have successfully reversed hyperglycemia in NOD mice, either alone or in combination with an ASI [13,19,20,21] and have recently been effective at delaying insulin production loss in pre-diabetic (i.e., dysglycemia, Stage 2) subjects [22].